<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03149939</url>
  </required_header>
  <id_info>
    <org_study_id>BN-0316</org_study_id>
    <nct_id>NCT03149939</nct_id>
  </id_info>
  <brief_title>Use of Febuxostat in Hyperuricemia Among Hemodialysis Patients</brief_title>
  <official_title>Use of Febuxostat in Hyperuricemia Among Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benha University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>New Jeddah Clinic Hospital</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Benha University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hyperuricemia is not infrequently encountered among hemodialysis patients. However, there is
      no clear data about use of febuxostat among hemodialysis patients, apart from very small case
      series. The aim of this study is to investigate the efficacy of using febuxostat for the
      treatment of Hyperuricemia among hemodialysis patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Actual">May 1, 2017</completion_date>
  <primary_completion_date type="Actual">April 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum uric acid</measure>
    <time_frame>at three months of Febuxostat 40 milligrams Tablet therapy</time_frame>
    <description>Change in serum uric acid after 3 months of Febuxostat 40 milligrams Tablet therapy</description>
  </primary_outcome>
  <enrollment type="Actual">19</enrollment>
  <condition>Hyperuricemia</condition>
  <condition>Hemodialysis Complication</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat 40 milligramsTablet</intervention_name>
    <description>Febuxostat 40 milligramsTablet every other day for 3 months</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age above 18 years

          -  Hemodialysis patient

          -  Hyperuricemia (Uric acid level above 6.0 mg/dL in females and 7.0 mg/dL in males)

        Exclusion Criteria:

          -  Patient currently and/or recently received drugs for hyperuricemia within the last
             three months

          -  Patient had recent (within 3 months) change of erythropoiesis stimulating drugs or
             other drug known to increase uric acid e.g furosemide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2017</study_first_submitted>
  <study_first_submitted_qc>May 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2017</study_first_posted>
  <last_update_submitted>May 10, 2017</last_update_submitted>
  <last_update_submitted_qc>May 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Benha University</investigator_affiliation>
    <investigator_full_name>Mahmoud Hamada imam</investigator_full_name>
    <investigator_title>MD. - Lecturer at Internal Medicine Department- Faculty of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Febuxostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

